Silicone Breast Implant (BIA-ALCL Risk, Textured Surface, Gel Migration, Capsular Contracture, FDA Black Box Warning) — household safety profile

What is this product?

Silicone gel-filled breast implants are among the most studied medical devices in history, with over 400,000 implanted annually in the United States for augmentation and reconstruction. In 2011, the FDA identified a rare but serious association between textured-surface breast implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a T-cell lymphoma of the peri-implant capsule with an estimated incidence of 1 in 2,207 to 1 in 86,029 depending on surface texturing type. Allergan Biocell textured implants were recalled worldwide in 2019 after accounting for approximately 80% of all BIA-ALCL cases. Beyond BIA-ALCL, silicone breast implants are associated with capsular contracture (10-20% incidence at 10 years), gel bleed (microscopic silicone migration through intact shells), implant rupture (10-15% at 10 years requiring MRI screening), and a constellation of systemic symptoms termed 'breast implant illness' (BII) — fatigue, cognitive dysfunction, joint pain, and autoimmune-like symptoms — that remains scientifically controversial but is reported by thousands of patients. The FDA issued a black box warning for breast implants in 2020 and mandated a patient decision checklist for informed consent.

What's in it

Click any compound name for its full safety profile, regulatory consensus, and exposure data.

No compound composition on file for this product.

Frequently asked questions

No FAQs generated.